Who to call at Liminatus Pharma, Inc., and when
Fundz watches for the moments Liminatus Pharma, Inc. starts buying, and tells you who to reach.
- An alert the day Liminatus Pharma, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Liminatus Pharma, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Liminatus Pharma, Inc.. With Fundz connected, it knows.
Liminatus Pharma, Inc.
The company signed a major contract or deal. An 8-K is the notice a US public company must file within four business days of a major event.
liminatuspharma.comExecutive Summary
Analysis of 8-K filing content
Liminatus Pharma secured $650,002.50 in private placement funding by issuing 260,001 shares at $2.50 per share to a non-U.S. investor, with closing expected November 20, 2026. The capital will support working capital and general corporate operations.
Quick answer
Liminatus Pharma, Inc. filed a Form 8-K with the SEC on November 3, 2026 under Item 1.01 (Entry into Material Agreement). Liminatus Pharma secured $650,002.50 in private placement funding by issuing 260,001 shares at $2.50 per share to a non-U.S. investor, with closing expected November 20, 2026.
- What did Liminatus Pharma, Inc. disclose in its 8-K filed November 3, 2026?
- Liminatus Pharma secured $650,002.50 in private placement funding by issuing 260,001 shares at $2.50 per share to a non-U.S. investor, with closing expected November 20, 2026. The capital will support working capital and general corporate operations.
- What does 8-K Item 1.01 (Entry into Material Agreement) mean?
- The company signed a major contract or deal. Companies generally must file it within four business days of the event.
- Which other companies filed an 8-K Item 1.01 around the same time?
- OpenWorld, Inc. (October 30, 2026) also filed an Item 1.01 8-K within a week of Liminatus Pharma, Inc.
- Where can I read the original Liminatus Pharma, Inc. filing?
- The original filing is on SEC EDGAR (CIK 0001971387), accession number 0001104659-26-122012.
Source: Fundz verified event record.
Other companies that filed an 8-K Item 1.01 (Entry into Material Agreement) the same week
Analyzed filings with the same item number within 7 days, from SEC EDGAR via Fundz.
- OpenWorld, Inc. (October 30, 2026): OpenWorld appointed Patrick Kim as CEO of Blocksight effective October 27, 2026, following the company's merger.
Key Takeaways
Company raised $650,002.50 through private placement of 260,001 common shares at $2.50 per share
Investor is a non-U.S. entity, indicating international investor interest in the company
2 more takeaways
Filing Overview
What This Means
Liminatus Pharma, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.